ANI Pharmaceuticals, Inc. (ANIP) on Decifer

Decifer ranks ANIP number 198 of 273 tracked names on durable business quality.

Why it ranks here

• Its returns on invested money are modest, around 6% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is growing about 44% a year, profits grew 437% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• It keeps issuing a lot of new shares, which dilutes its owners.
• Profits up 437% with revenue up 44% is strong, but modest returns of 6% and heavy share issuance with momentum of 4 hold it back.

The current read

The evidence on ANIP lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Read the full ANIP research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.